All In Biotech

Drug Trial Radar · NCT07068958

A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye

A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Nov 1, 2025

Study completion Nov 1, 2025

Sponsor

Lead sponsor
ORA, Inc.Industry
Sponsor type
Industry
First posted
Jul 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution twice a day (BID) and four times a day (QID) compared to placebo (vehicle) in the treatment of the signs and symptoms of dry eye. The secondary objective of this study is to evaluate the optimal dosing frequency of 0.25% RCI001 Ophthalmic Solution (BID versus QID) in the treatment of the signs and symptoms of dry eye.

Conditions

  • Dry Eye Disease (DED)

Interventions

  • 0.25% RCI001 Ophthalmic SolutionDrug

    0.25% RCI001 Ophthalmic Solution

  • Placebo Ophthalmic Solution (vehicle)Drug

    Placebo Ophthalmic Solution (vehicle)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Corneal staining sign measured with the Ora Calibra® Corneal and Conjunctival Staining Scale, and Ocular Discomfort symptom measured with Ora Calibra® Ocular Discomfort Scale in subjects dosed with 0.25% RCI001 Ophthalmic Solution BID, QID or PlaceboTime frame: 4 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.